Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN)
Phase 1
Completed
- Conditions
- Vulvar Intraepithelial Neoplasia Grade 2Vulvar Intraepithelial Neoplasia Grade 3
- Interventions
- Drug: VTD-101 ointment
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- ViMREX GmbH
- Target Recruit Count
- 29
- Registration Number
- NCT05717621
- Locations
- 🇩🇪
Dysplasiezentrum HH am Krankenhaus Jerusalem, Hamburg, Germany
🇩🇪St. Elisabeth Krankenhaus Köln, Klinik für Gynäkologie und Geburtshilfe, Köln, Germany
🇩🇪Universitätsklinikum Augsburg, Klinik für Frauenheilkunde und Geburtshilfe, Augsburg, Bavaria, Germany
© Copyright 2025. All Rights Reserved by MedPath